Omne Possibile launched to harness transformative power of XNA in 
healthcare, information technology and smart materials 
 
   A pioneering, global technological leader in XNA creating customizable 
structures to outperform current DNA and RNA technologies 
 
   XNA is at the forefront of the synthetic biology revolution, forecast to 
transform medicine, agriculture, energy, consumer products and IT with a 
$4 trillion annual economic impact 
 
   Founded by leading European synthetic biologists 
 
   Leuven, Belgium, and Basel, Switzerland -- 10 May 2021: Omne Possibile 
("the Company"), a global synthetic biology company pioneering the XNA 
revolution, has been launched today to harness the power of XNA (xeno 
nucleic acids) to transform medicine, agriculture, energy, consumer 
products and information technology. XNA is at the forefront of the 
synthetic biology revolution, designed to overcome the constraints of 
the chemical structures of DNA and RNA technologies. It is forecast to 
have a $4 trillion annual economic impact over the next 10 to 20 years, 
greater than that of the internet.(1) 
 
   Patrice Garnier, President and Chief Executive Officer of Omne Possibile, 
said: "Synthetic biology has been called the fifth industrial 
revolution. We believe XNA will be the dominant technology of the 21st 
century, with a profound impact on all aspects of our daily lives 
including healthcare, information technology, energy, transport and 
consumer goods. Omne Possibile unites leading European experts in the 
critical building blocks of synthetic biology and the key disciplines of 
XNA development. Our ambition is to convert Europe's advances in XNA 
technology into a global company that will lead the revolution in 
synthetic genetics." 
 
   "Xenobiology will be to biology what astronautics has been to 
astronomy." adds Philippe Marlière, Chairman of the Board of Omne 
Possibile. "Through the diversification of the base alphabet and 
backbone motifs of DNA and RNA analogs, our company will provide the 
industry with a plethora of customized genetic polymers. Having brought 
together the most forward-thinking scientists and industrialists in the 
field, including two Nobel laureates, Omne Possibile is set to bring 
genetic polymers to market." 
 
   Omne Possibile was co-founded by Patrice Garnier, an entrepreneur with 
more than 20 years of experience leading high-tech companies, Alexandre 
Mouradian, a seasoned and visionary investor, and by three of Europe's 
leading synthetic biologists: Philippe Marlière, Scientific 
Director at ISSB Evry; Piet Herdewijn, Professor of Medicinal Chemistry 
at KU Leuven; Sven Panke, Professor of Bioprocess Engineering at ETH 
Zürich. 
 
   The Company will initially focus on development of XNA polymers for 
information storage and XNA building blocks for improved messenger 
therapeutics: 
 
 
   -- Storage XNA (sXNA) are seen as ideal candidates to manage the exponential 
      growth of data in the coming decades, offering benefits in terms of 
      capacity, energy use, space requirements and cost. 
 
   -- Messenger XNA (mXNA) is designed to overcome the limitations of mRNA, the 
      backbone of modern vaccine technologies in areas like viral infections 
      and cancer. They also play key roles in genetic treatments and in 
      agricultural pest control. mXNA offers the potential for greatly improved 
      chemical functionality and biological stability, opening up significant 
      new opportunities in healthcare and other fields. 
 
 
   Omne Possibile combines the key disciplines of XNA development, 
including chemical synthesis, genetics, directed evolution of enzymes 
and genomes, automated design of molecules, and bioproduction pathways. 
It has established an R&D innovation center in Leuven, Belgium, to focus 
on XNA chemistry, and a second R&D hub in Basel, Switzerland, dedicated 
to XNA genetics. It intends to grow rapidly through a combination of 
in-house development and industrial collaborations. 
 
   A scientific advisory board of leading industrialists and globally 
renowned scientists will be announced in the next few weeks to guide the 
Company's strategy. 
 
   -End- 
 
   About Omne Possibile 
 
   Omne Possibile is a pioneering, global technological leader in XNA, 
creating customizable structures to outperform current DNA and RNA 
technologies. Its goal is to harness the transformative power of XNA in 
areas including healthcare, information technology and smart materials. 
The Company's initial focus is on development of XNA polymers for 
information storage and XNA building blocks for improved messenger 
therapeutics. Omne Possibile has R&D hubs in Leuven, Belgium, and Basel, 
Switzerland. It was founded by leading European synthetic biologists and 
is supported by a world class scientific advisory board. For more 
information, please visit www.omnepossibile.com 
 
   Contact 
 
   Omne Possibile 
 
   Patrice Garnier, Chief Executive Officer 
 
   info@omnepossibile.com 
https://www.globenewswire.com/Tracker?data=UOmY7SFCqIYvTfWFo7flaW7zlx0dMI0pc-4eEp_mY93ikAfduRAMVeHnbJC01bpDUOHRmTIR118HUv2A0LXjPS-dDT-iIxxti2I9Nc4EASI= 
 
 
   Consilium Strategic Communications 
 
   Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs 
 
   +44 (0) 203 709 5000 
 
   eurekare@consilium-comms.com 
https://www.globenewswire.com/Tracker?data=9DA-ileyHMyhd8skNjeJldmYOze3q_l5On0_l1nFbwSmN9ITmhBniJP4yq-J7bbTe-yxA7Z-Yz5ApeshZSLxc8RCnYzuYos-Z7J4SOcSfhJPzKa8gkhhD8kPqlWPnH2e 
 
 
   (1) How the Bio Revolution could transform the competitive landscape, 
Michael Chui, Matthias Evers, Alice Zheng, McKinsey Quarterly, May 2020

(END) Dow Jones Newswires

May 10, 2021 02:00 ET (06:00 GMT)